Molecular Instruments & Empire Genomics Launch Nish - May 5

The Story

Empire Genomics, a Biocare Medical company, and Molecular Instruments announced on May 5, 2026 the launch of NISH, described as the largest ready-to-use, fully automated in situ hybridization (ISH) library. The offering, powered by HCR™ Pro, is being made exclusively available worldwide on the NeoPATH Pro platform, the companies said in a joint press release from Los Angeles and Buffalo, N.Y.

Why It Matters For Your Portfolio

• Launch Date and Scope: The product was announced on May 5, 2026 and is positioned as the largest ready-to-use, fully automated ISH library, which may drive adoption among clinical and research labs that use ISH workflows.
• Exclusive Distribution: Being exclusively available worldwide on NeoPATH Pro centralizes commercial access, which could influence purchase and upgrade cycles for customers of NeoPATH Pro.
• Strategic Partnership: The collaboration links Molecular Instruments, founded by the inventor of HCR technology, with Empire Genomics and Biocare Medical, potentially expanding each company’s commercial reach and platform integration.
• Operational Impact: Labs and service providers using NeoPATH Pro may see simplified, automated ISH options, which could affect procurement decisions for pathology and molecular diagnostics equipment suppliers.

The Trade

Growth-oriented investors tracking diagnostics platforms, pathology automation, or molecular assay providers should note this strategic launch and exclusive distribution. Watch for follow-up commercial updates from Empire Genomics, Molecular Instruments, and NeoPATH Pro on adoption metrics, customer rollouts, or expanded product listings to gauge market traction.